Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial GlobeNewswire - Mon May 5, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 2.20 (unch)
Aptose Announces Auditor Not Standing for Re-Appointment GlobeNewswire - Wed Apr 23, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 2.20 (unch)
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference GlobeNewswire - Wed Apr 23, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 2.20 (unch)
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025 GlobeNewswire - Tue Apr 1, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 2.20 (unch)
Aptose Reports Year End 2024 Results and Corporate Highlights GlobeNewswire - Fri Mar 28, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 2.20 (unch)
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance GlobeNewswire - Mon Mar 17, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 2.20 (unch)
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort GlobeNewswire - Thu Feb 20, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 2.20 (unch)
Aptose Announces Reverse Share Split GlobeNewswire - Tue Feb 18, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 2.20 (unch)
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility GlobeNewswire - Thu Feb 13, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 2.20 (unch)
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial GlobeNewswire - Wed Feb 12, 2025

APTO : 1.7100 (-45.71%)
APS.TO : 2.20 (unch)

Barchart Exclusives

Should You Buy Dividend-Paying Gold Stocks as Trump Makes Them ‘Great Again’? Barchart - Tue Jan 13, 6:30PM CST
Gold stocks have soared over the last year amid the rally in gold prices. Miners are paying handsome dividends as their cash flows have tracked gold prices higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot